A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Dobutamine
4-Hydroxytestosterone
The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Dexamethasone.
Dobutamine
1-Testosterone
The risk or severity of edema formation can be increased when 1-Testosterone is combined with Dexamethasone.
Dobutamine
Bolasterone
The risk or severity of edema formation can be increased when Bolasterone is combined with Dexamethasone.
Dobutamine
19-norandrostenedione
The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Dexamethasone.
Dobutamine
Nandrolone phenpropionate
The risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Dexamethasone.
Dobutamine
Trilostane
The risk or severity of edema formation can be increased when Trilostane is combined with Dexamethasone.
Dobutamine
Osimertinib
The metabolism of Osimertinib can be increased when combined with Dexamethasone.
Dobutamine
Phenylacetic acid
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Dexamethasone.
Dobutamine
Glycerol phenylbutyrate
The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Dexamethasone.
Dobutamine
Phenylbutyric acid
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Dexamethasone.
Dobutamine
Benzoic acid
The therapeutic efficacy of Benzoic acid can be decreased when used in combination with Dexamethasone.
Dobutamine
Alcuronium
The risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Dexamethasone.
Dobutamine
Gallamine
The risk or severity of myopathy and weakness can be increased when Gallamine is combined with Dexamethasone.
Dobutamine
Atracurium
The risk or severity of myopathy and weakness can be increased when Atracurium is combined with Dexamethasone.
Dobutamine
Neosaxitoxin
The risk or severity of myopathy and weakness can be increased when Neosaxitoxin is combined with Dexamethasone.
Dobutamine
Pyrantel
The risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Dexamethasone.
Dobutamine
Rapacuronium
The risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Dexamethasone.
Dobutamine
Vecuronium
The risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Dexamethasone.
Dobutamine
Metocurine
The risk or severity of myopathy and weakness can be increased when Metocurine is combined with Dexamethasone.
Dobutamine
Mivacurium
The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Dexamethasone.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3